BETA Technologies launches IPO of 25 million shares priced $27-$33
Investing.com -- Vyome Holdings Inc. (NASDAQ:HIND) stock surged 55% in premarket trading Wednesday following the company’s presentation of positive preclinical study results for its eye inflammation treatment VT-1908 at the American Society for Pharmacology and Experimental Therapeutics annual meeting.
The company reported that its topical mycophenolate formulation demonstrated efficacy similar to commonly used steroids in treating anterior uveitis, the most common form of eye inflammation. According to Vyome, twice-daily application of VT-1908 eye drops reduced uveitis scores comparably to steroids currently used as first-line therapy.
Uveitis causes approximately 30,000 new cases of legal blindness annually in the United States. Current steroid treatments often come with complications including cataracts and increased eye pressure that can lead to glaucoma, creating a potential market opportunity for alternative treatments.
"The fact that VT-1908 is as effective as a steroid is exciting as we can aim to replace steroids in the eye, which are associated with a number of complications," said Dr. Shiladitya Sengupta, co-founder of Vyome and associate professor of medicine at Harvard Medical School.
The company plans to initiate a Phase 1/2 clinical trial for VT-1908 in the second half of 2026, according to CEO Venkat Nelabhotla. Vyome initially aims to target uveitis treatment before potentially expanding to broader ocular inflammation applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.